Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.43 |
| ▸ | UBE2M | P61081 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081057 | 0.89 | MEN1 (0.55) | GCGRCA12CA1CA9KMT2A | |
| SCHEMBL4081372 | 0.87 | TRPV1 (0.54) | GCGRNPC1RAB9AHDAC6HDAC1 | |
| SCHEMBL4086790 | 0.85 | DCUN1D1 (0.42) | GCGRDCUN1D1HDAC6HDAC1TRPV1 | |
| SCHEMBL4085611 | 0.85 | KDM4E (0.43) | GCGRNPC1RAB9AHDAC6HDAC1 | |
| SCHEMBL9072666 | 0.85 | GCGR (0.55) | GCGRKMT2AMEN1MAPT | |
| SCHEMBL4091875 | 0.84 | GCGR (0.70) | GCGRCA12CA1CA9KMT2A | |
| SCHEMBL4096168 | 0.84 | GCGR (0.52) | GCGRCA12CA1CA9KMT2A | |
| SCHEMBL4091869 | 0.82 | ABCG2 (0.46) | CA12CA1CA9KMT2AMEN1 | |
| SCHEMBL2663227 | 0.79 | GCGR (0.64) | GCGR | |
| SCHEMBL4092347 | 0.77 | GCGR (0.51) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | GCGR 3/4885CA12 4759/4885CA1 4464/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885CA12 4759/4885CA1 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.